Advances in CRISPR-based gene editing and stem cell-derived embryo models have created new therapeutic possibilities alongside ethical and distributive concerns. Approved genomic and regenerative therapies in the United States carry list prices reported roughly between $2.2 million and $4.25 million, raising questions about affordability and access. The original Genomic Equity Accessibility Framework (GEAF) aimed to combine affordability, accessibility, ethical compliance, and inequality into a single index for policy comparison, but its original formulation exhibited mathematical and interpretive flaws.
This manuscript focuses on methodological reconstruction rather than empirical clinical evaluation. Primary objectives were to (1) reconstruct GEAF into a dimensionally consistent, bounded, and monotonic composite (RQ1–RQ2), (2) characterize parameter influence via sensitivity analyses (RQ2), (3) situate the reconstructed index relative to established economic and equity frameworks (RQ3), and (4) specify data required for empirical calibration and validation (RQ4). The unit of analysis is a therapy–jurisdiction–policy scenario, not patient-level outcomes or ICERs.
The paper summarizes ethical debates motivating the equity questions without attempting to resolve them. Topics include non-therapeutic genetic enhancement and related procreative beneficence versus deontological critiques and historical concerns about eugenics; the moral status and governance of stem cell-derived embryo models (blastoids, gastruloids) and the ISSCR guideline updates; and cross-jurisdictional variability in stem cell research regulation, consent standards, and oversight.
Three conceptual governance mechanisms are proposed as discussion starters (not implemented institutions): Ethical Enhancement Councils (EECs), a Tiered Moral Framework (TMF), and International Stem Cell Accords (ISCAs). These mechanisms are presented as starting points for policy discussion and are operationalized in the manuscript’s tables.
The submitted formula was GEAF = ((A × E) – (C × I))/(P + R) × 100 where A is accessibility (0–100), E ethical compliance (0–1), C cost in thousands, I inequality (0–1), P policy strength (1–10), and R research-efficiency (0–1). The audit applied four standard criteria for multi-criteria index construction:
Dimensional consistency: Multiplying or subtracting quantities on incompatible scales (percent × probability versus cost × coefficient) produces numerically dominated outputs; C × I overwhelmed A × E.
Boundedness and interpretability: The numerator was unbounded below and the denominator could be near 1, yielding an index with no defined minimum or maximum and reported values spanning large negative to large positive ranges without clear meaning.
Denominator behavior: Putting (P + R) in the denominator created counterintuitive behavior where increasing policy strength or research efficiency could move a negative numerator toward zero without an interpretable notion of “better.”
Scenario–formula consistency: Illustrative scenarios in the original manuscript used cost inputs far below cited list prices, creating an internal inconsistency.
On this basis the author concluded the original GEAF could not be fixed by simple re-normalization and required reconstruction from first principles.
GEAF’ was reconstructed using multi-attribute utility theory. Six input variables are transformed into direction-consistent, dimensionless components on [0,1], where 1 is the most favorable state for equity and access. The six components are: accessibility, ethical compliance, affordability, equity (inverse of inequality), policy strength, and research efficiency. Components are combined as a weighted arithmetic mean and rescaled to a 0–100 index.
Equal weighting (w = 1/6) is used as a transparent default in the absence of empirically derived weights; unequal weighting is noted as an explicit avenue for future stakeholder-based work. Affordability is normalized using a ceiling (C_max) to set the point at which the affordability component reaches its floor of 0. In this manuscript C_max was set to $4.25 million (4,250 in thousands), anchored to a cited highest publicly reported list price (Lenmeldy) for normalization purposes only; the author emphasizes that outputs are sensitive to this choice and that it is not an affordability estimate.
This reconstruction meets four validity requirements: all components share a common scale before combination; the index is bounded on [0,100]; the arithmetic-mean structure avoids denominator-driven distortions; and scenario cost inputs were re-specified to be consistent with the cited cost literature.
Table 2 in the manuscript summarizes definitions, scales, sources, and evidentiary status for each parameter. The study is conceptual and used no primary data; all reported scores are outputs of the deterministic formula or stochastic simulations built on that formula. Seven illustrative scenarios were re-specified with cost inputs anchored to cited list-price literature to address prior inconsistencies.
GEAF’ is algebraically bounded on [0,100], monotonic in every component, and behaves consistently at algebraic extremes. Applied to seven re-specified illustrative scenarios, GEAF’ produced scores ranging from 27.9 for a no-equity-intervention, list-price-cost scenario to 86.5 for a fully optimized tiered-pricing and policy scenario. The manuscript reports that GEAF’ outputs are sensitive to the choice of affordability ceiling and to component values, as expected for a composite index.
One-way sensitivity analysis identified treatment cost (C) and the inequality factor (I) as the two largest single-parameter drivers of GEAF’ under baseline conditions, followed by ethical compliance (E). Two-way analyses and a Monte Carlo probabilistic sensitivity analysis (10,000 iterations per regime) were conducted under stated non-empirical parameter-uncertainty assumptions. The Monte Carlo results produced a baseline-scenario mean GEAF’ of 32.6 (90% interval approximately 22.9–42.9) and an equity-intervention-scenario mean of 72.4 (90% interval approximately 62.9–81.1), with no overlap between simulated distributions under the specified assumptions.
GEAF’ offers a transparent, reproducible, and dimensionally coherent method to combine affordability, accessibility, ethical compliance, and distributional equity into a single comparative index for genomic and regenerative therapy policy scenarios. The author frames GEAF’ as a candidate conceptual and methodological framework rather than an empirically validated predictive or clinical tool. Quantitative claims about real-world cost reductions were removed unless directly supported by cited evidence. The manuscript identifies prospective empirical calibration against real accessibility, pricing, and policy-outcome data as a necessary next step before GEAF’ is suitable for health-technology assessment or resource-allocation decisions. All analysis code used to generate reported scores and sensitivity results is provided in the supplement.